Cobicistat Compared With Ritonavir as a Pharmacoenhancer for Atazanavir in Combination With Emtricitabine/Tenofovir Disoproxil Fumarate: Week 144 Results

被引：23

作者：

Gallant, Joel E. ^{[1
]}

Koenig, Ellen ^{[2
]}

Andrade-Villanueva, Jaime F. ^{[3
]}

Chetchotisakd, Ploenchan ^{[4
]}

DeJesus, Edwin ^{[5
]}

Antunes, Francisco ^{[6
]}

Arasteh, Keikawus ^{[7
]}

Rizzardini, Giuliano ^{[8
]}

Fehr, Jan ^{[9
]}

Liu, Hui C. ^{[10
]}

Abram, Michael E. ^{[10
]}

Cao, Huyen ^{[10
]}

Szwarcberg, Javier ^{[10
]}

机构：

[1] Southwest CARE Ctr, Santa Fe, NM USA

[2] Inst Dominicano Estudios Virolog, Santo Domingo, Dominican Rep

[3] Hosp Civil Guadalajara, HIV Unit, Guadalajara, Jalisco, Mexico

[4] Khonkaen Univ, Dept Med, Khon Kaen, Thailand

[5] Orlando Immunol Ctr, Orlando, FL USA

[6] Fac Med Lisbon, Inst Saude Ambiental, Lisbon, Portugal

[7] Vivantes Auguste Viktoria Klinikum, EPIMED, Berlin, Germany

[8] Luigi Sacco Hosp, Dept Infect Dis, Milan, Italy

[9] Univ Zurich, Univ Zurich Hosp, Div Infect Dis & Hosp Epidemiol, Zurich, Switzerland

[10] Gilead Sci Inc, Foster City, CA 94404 USA

来源：

JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES | 2015年 / 69卷 / 03期

关键词：

Cobicistat; pharmacoenhancer; HIV; Antiretroviral; clinical trial; INITIAL TREATMENT; TREATMENT-NAIVE; DOUBLE-BLIND; LOPINAVIR/RITONAVIR; PHARMACOKINETICS; INFECTION; GS-9350; REGIMEN;

D O I：

10.1097/QAI.0000000000000598

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Background:Cobicistat (COBI) is a pharmacoenhancer with no antiretroviral activity.Methods:International, randomized double-blind active-controlled trial to evaluate the efficacy and safety of COBI vs ritonavir (RTV) as a pharmacoenhancer of atazanavir in combination with emtricitabine/tenofovir disoproxil fumarate in HIV treatment-naive patients followed through week 144.Results:At Week 144, virologic suppression was achieved in 72% (COBI) and 74% (RTV) of patients. Adverse events leading to study drug discontinuation occurred in 11% of patients in each group. Median changes in serum creatinine (mg/dL) were +0.13 (COBI) and +0.07 (RTV) and were unchanged from week 48.Conclusions:Once-daily COBI is a safe and effective pharmacoenhancer of the protease inhibitor atazanavir.

引用

页码：338 / 340

页数：3

共 50 条

[41] A Randomized, Double-Blind Comparison of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate, Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine for Initial HIV-1 Treatment: Week 96 Results
Wohl, David
Oka, Shinichi
Clumeck, Nathan
Clarke, Amanda
Brinson, Cynthia
Stephens, Jeffrey
Tashima, Karen
Arribas, Jose R.
Rashbaum, Bruce
Cheret, Antoine
Brunetta, Jason
Mussini, Cristina
Tebas, Pablo
Sax, Paul E.
Cheng, Andrew
Zhong, Lijie
Callebaut, Christian
Das, Moupali
Fordyce, Marshall
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2016, 72 (01) : 58 - 64
[42] Nevirapine versus atazanavir/ritonavir, each combined with tenofovir disoproxil fumarate/emtricitabine, in antiretroviral-naive HIV-1 patients: the ARTEN Trial
Soriano, Vicente
Arasteh, Keikawus
Migrone, Horacio
Lutz, Thomas
Opravil, Milos
Andrade-Villanueva, Jaime
Antunes, Francisco
Di Perri, Giovanni
Podzamczer, Daniel
Taylor, Steve
Domingo, Pere
Gellermann, Holger
de Rossi, Lothar
ANTIVIRAL THERAPY, 2011, 16 (03) : 339 - 348
[43] Renal function in antiretroviral-experienced patients treated with tenofovir disoproxil fumarate associated with atazanavir/ritonavir
Gerard, Laurence
Chazallon, Corine
Taburet, Anne-Marie
Girard, Pierre-Marie
Aboulker, Jean-Pierre
Piketty, Christophe
ANTIVIRAL THERAPY, 2007, 12 (01) : 31 - 39
[44] Week 144 resistance analysis of elvitegravir/cobicistat/emtricitabine/tenofovir DF versus efavirenz/emtricitabine/tenofovir DF in antiretroviral-naive patients
White, Kirsten L.
Kulkarni, Rima
McColl, Damian J.
Rhee, Martin S.
Szwarcberg, Javier
Cheng, Andrew K.
Miller, Michael D.
ANTIVIRAL THERAPY, 2015, 20 (03) : 317 - 327
[45] Darunavir/elvitegravir/emtricitabine/tenofovir-disoproxil-fumarate/cobicistat/voriconazoleDecrease in AUC for darunavir and voriconazole: case report
Reactions Weekly, 2017, 1659 (1) : 94 - 94
[46] Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate Triple Combination TabletA Viewpoint by Paul Volberding
Paul Volberding
Drugs, 2006, 66 : 1513 - 1514
[47] Elvitegravir/cobicistat/emtricitabine/tenofovir DF (Quad) has durable efficacy and differentiated safety compared to atazanavir boosted by ritonavir plus emtricitabine/tenofovir DF at week 96 in treatment-na ve HIV-1-infected patients
Rockstroh, J.
DeJesus, E.
Henry, K.
Molina, J.
Gathe, J.
Wei, X.
Fordyce, X.
Rhee, M.
Szwarcberg, J.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2012, 15 : 23 - 23
[48] Emtricitabine/Tenofovir Disoproxil Fumarate In Combination with a Protease Inhibitor in HIV-1 Infection
Perry, Caroline M.
DRUGS, 2009, 69 (07) : 843 - 857
[49] Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial
Venter, Willem D. F.
Sokhela, Simiso
Simmons, Bryony
Moorhouse, Michelle
Fairlie, Lee
Mashabane, Nkuli
Serenata, Celicia
Akpomiemie, Godspower
Masenya, Masebole
Qavi, Ambar
Chandiwana, Nomathemba
McCann, Kaitlyn
Norris, Shane
Chersich, Matthew
Maartens, Gary
Lalla-Edward, Samanta
Vos, Alinda
Clayden, Polly
Abrams, Elaine
Arulappan, Natasha
Hill, Andrew
LANCET HIV, 2020, 7 (10): : E666 - E676
[50] Prophylaxis by doravirine-lamivudine-tenofovir disoproxil fumarate or elvitegravir-cobicistat-emtricitabine-tenofovir alafenamide after sexual exposure to HIV
Inès Devred
Kick Kayembe
Nadia Valin
Hayette Rougier
Bruce Wuembulua Shinga
Sidonie Lambert-Niclot
Thibault Chiarabini
Marie-Caroline Meyohas
Karine Lacombe
BMC Infectious Diseases, 23

← 1 2 3 4 5 →